CClinicalTrials.gg
Sign In
RecruitingNCT07113769ECPRUpdated Mar 23, 2026

Plasma Biomarkers and Platelet Morphology of Extracorporeal CardioPulmonary Resuscitation

An observational study in ExtraCorporeal Membrane Oxygenation (ECMO) and Cardiac Arrest, sponsored by Central China Fuwai Hospital of Zhengzhou University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by Central China Fuwai Hospital of Zhengzhou University · Observational

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
130
Ages
18 Years and older
Sex
All
01

Study summary

Extracorporeal cardiopulmonary resuscitation (ECPR) constitutes a pivotal emergency intervention for cardiac arrest (CA) patients. However, current eligibility criteria and prognostic assessment metrics remain substantially limited, relying predominantly on clinical symptoms and physical signs while lacking objective biomarker data. Integrating reproducible, highly sensitive, and specific proteinaceous and metabolic indicators with ultrastructural platelet alterations may hold significant implications for both ECPR administration and prognostication in CA. Therefore, the purpose of this study is to identify the plasma proteomic and metabolomic characteristics of patients with refractory cardiac arrest before and after ECPR treatment, as well as the characteristics of platelet morphological and structural changes, to search for potential specific markers that can predict CA patients who may benefit from ECPR so as to optimize treatment selection.

02

Conditions studied

  • ExtraCorporeal Membrane Oxygenation (ECMO)
  • Cardiac Arrest

Browse trials for

03

In context

Heart Arrest

966 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

This study's planned enrollment of 130 is below the median of 200 across 383 observational studies indexed under Heart Arrest.

Browse Heart Arrest studies →

Lead sponsor

Central China Fuwai Hospital of Zhengzhou University is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All adult patients receiving ECPR will be included. The decision to perform an ECPR is made by the local protocol and clinical judgment of the attending physician.

Inclusion criteria

  1. Age between 18 and 70 years old (the age limit can be relaxed if the patient has good organ function and a good neurological prognosis after evaluation).
  2. The cardiac arrest is witnessed, and bystanders perform traditional cardiopulmonary resuscitation (CPR), and the time interval from the occurrence of cardiac arrest to the start of traditional CPR is no more than 5 minutes.
  3. The causes of cardiac arrest are reversible, such as cardiogenic, pulmonary embolism, severe hypothermia, drug poisoning, trauma, acute respiratory distress syndrome, etc.
  4. After 20 minutes of traditional CPR, there is no restoration of spontaneous circulation or hemodynamic instability, or the restoration of spontaneous circulation occurs, but the spontaneous heart rhythm cannot be maintained.
  5. The informed consent has been signed.

Exclusion criteria

Exclusion Criteria:

  1. Infectious diseases, such as hepatitis B, hepatitis C, AIDS, syphilis, etc.
  2. Hematological diseases, such as hematological malignancies, aplastic anemia, idiopathic thrombocytopenic purpura (ITP), etc.
  3. Malignant tumors in other systems except the hematological system.
  4. Patients who have received massive plasma or platelet transfusions during hospitalization or recently.
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
130 participants (estimated)
Target follow-up
1 Month
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • CA patients who have fully recovered after receiving ECPR treatment
  • CA patients with organ dysfunction after receiving ECPR treatment
  • CA patients who died or suffered brain death after receiving ECPR treatment
06

What researchers measure

Primary outcomes

  1. 30 day mortality

    Time frame: Within 30 days after ECPR

  2. Hospital survival

    Time frame: Within 30 days after ECPR

Secondary outcomes

  1. Cerebral Performance Category (CPC) scale

    Cerebral Performance Category scale Range: 1 to 5 Interpretation: Lower scores indicate better neurological outcome (1 = good cerebral performance, 5 = brain death or severe vegetative state)

    Time frame: 30 days after ECPR

  2. Left Ventricular Ejection Fraction (LVEF)

    Time frame: Within 30 days after ECPR

  3. PaO2/FiO2 ratio

    Time frame: Within 30 days after ECPR

  4. Serum Bilirubin level

    Time frame: Within 30 days after ECPR

  5. Serum Creatinine level

    Time frame: Within 30 days after ECPR

07

Study locations

1 of 1 sites recruiting
  • Fuwai Central China Cardiovascular Hospital
    Zhengzhou, Henan, China
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07113769
Lead sponsor
Central China Fuwai Hospital of Zhengzhou University
Collaborators
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Henan Provincial People's Hospital
Responsible party
Jianchao, Li (Principal Investigator, Central China Fuwai Hospital of Zhengzhou University) — Principal investigator
First posted
Aug 11, 2025
Start date
Sep 1, 2025
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Mar 23, 2026

Study contacts

Jianchao Li
Contact
381226651@qq.com
+86 185 3998 9191

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Heart Arrest→

Other studies from this sponsor

Central China Fuwai Hospital of Zhengzhou University

Start the discussion